Valuation: Natera, Inc.

Market Cap 59.72B 53.48B 49.2B 44.58B 83.32B 5,670B 84.88B 587B 236B 2,983B 224B 219B 9,407B P/E 2026 *
-289x
P/E 2027 * -3,694x
Enterprise Value 58.63B 52.51B 48.3B 43.76B 81.81B 5,567B 83.34B 576B 231B 2,928B 220B 215B 9,235B EV / Sales 2026 *
20.1x
EV / Sales 2027 * 16.6x
Free-Float
97.24%
Yield 2026 *
-
Yield 2027 * -
1 day-4.98%
1 week+2.56%
Current month+0.24%
1 month+0.24%
3 months+53.64%
6 months+100.96%
Current year+80.85%
1 week 400
Extreme 400
436.19
1 month 380.39
Extreme 380.39
437.41
Current year 181
Extreme 181
437.41
1 year 181
Extreme 181
437.41
3 years 38
Extreme 38
437.41
5 years 26.1
Extreme 26.1
437.41
10 years 7.35
Extreme 7.35
437.41
Manager TitleAgeSince
Chief Executive Officer 47 01/01/2019
President 46 31/08/2023
Director of Finance/CFO 45 31/01/2017
Director TitleAgeSince
Chairman 53 30/04/2015
Director/Board Member 53 31/12/2006
Director/Board Member 47 01/01/2019
Date Insider Type Main position Quantity % Market Cap. Importance
15/10/26 Exercice

Founder

150,000 0.1041%
07/10/26 Don

Founder

-6,000 0.0042%
01/10/26 Sell

Chief Executive Officer

-1,273 0.0009%
Change 5-day change 1-year change 3-year change Capi.($)
-4.98%+2.56%+114.42%+1,003.33% 59.72B
-0.09%-3.44%+17.68%+32.70% 115B
-1.02%+0.89%+1.37%+111.87% 98.85B
-1.84%+9.86%+43.22%+82.37% 29.34B
+1.44%+1.95%-6.67%+93.57% 30.06B
-0.43%+4.11%+43.28%+94.59% 27.71B
+0.99%+1.79%+30.98%+413.15% 22B
-0.72%+5.53%-18.63%-12.38% 20.66B
0.00%-0.63%-4.27%+31.71% 17.09B
-2.07%-27.56%-25.98%+45.52% 12.72B
Average -0.87%-0.49%+19.54%+189.64% 43.36B
Weighted average by Cap. -1.04%+0.23%+25.76%+213.47%

Financials

2026 *2027 *
Net sales 2.91B 2.61B 2.4B 2.17B 4.06B 276B 4.14B 28.59B 11.48B 145B 10.92B 10.69B 458B 3.52B 3.15B 2.9B 2.63B 4.91B 334B 5B 34.56B 13.87B 176B 13.2B 12.92B 554B
Net income -203M -182M -167M -152M -284M -19.3B -289M -2B -802M -10.15B -763M -747M -32.01B -8.5M -7.61M -7M -6.35M -11.86M -807M -12.08M -83.52M -33.53M -425M -31.91M -31.23M -1.34B
Net Debt -1.09B -975M -897M -813M -1.52B -103B -1.55B -10.69B -4.29B -54.37B -4.09B -4B -171B -1.4B -1.26B -1.16B -1.05B -1.96B -133B -2B -13.79B -5.54B -70.13B -5.27B -5.16B -221B
Projected Income Statement - Annual - Natera, Inc.
Logo Natera, Inc.
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
Employees
6,138
Date Price Change Volume
30/10/26 US$414.30 -4.98% 2,432,183
29/10/26 US$436.00 +2.73% 1,326,459
28/10/26 US$424.42 +3.31% 1,548,874
27/10/26 US$410.82 +1.46% 1,713,547
26/10/26 US$404.90 +0.24% 1,429,671
Trader
Investor
-
Global
-
Quality
ESG MSCI
BB
MarketScreener Ratings - Natera, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
414.30USD
Average target price
416.39USD
Spread / Average Target
+0.50%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Natera, Inc.
  1. Stock Market
  2. Stocks
  3. NTRA Stock